IMPLANTATION/MOUSE RENAL ADENOCARCINOMA/MACROBEADS/CANCER

植入/小鼠肾腺癌/大珠/癌症

• 批准号: 7378411
• 负责人: BARRY SMITH
• 金额: $ 10.21万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378411
• 关键词: IMPLANTATION; MOUSE; RENAL; ADENOCARCINOMA; MACROBEADS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the safety and toxicity of a 6-8mm agarose-agarose macrobead containing mouse renal adenocarcinoma cells (RENCA cells) in ten human patients with end-stage, treatment-resistant epithelial-derived cancer originating in the peritoneal cavity over a six-month period. The macrobeads, which have shown promise as inhibitors of a broad-range of epithelial-derived cancers both in vitro and vivo in murine models and veterinary patient studies, will be implanted in the peritoneal cavities of these patients at dosage levels of 8 macrobeads per kilogram (5 patients) and 16 macrobeads per kilogram (5 patients). Based on the progress to date and the absence of evidence of any significant toxicity directed related to the macrobeads (as opposed to complications of the underlying malignant disease process in its end-stages), we expect to increase entry into the study over the next several months, pending, of course, FDA and IRB approval of such an accelerated schedule.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是评估6-8mm琼脂糖-琼脂糖大珠含有小鼠肾腺癌细胞（RENCA细胞）的安全性和毒性，用于10例来自腹腔的终末期耐药上皮源性癌症患者，为期6个月。在体外和体内小鼠模型和兽医患者研究中，这些巨珠已显示出作为多种上皮源性癌症抑制剂的前景，将以每公斤8个巨珠（5例）和每公斤16个巨珠（5例）的剂量水平植入这些患者的腹膜腔。基于迄今为止的进展，以及没有证据表明与巨珠相关的任何重大毒性（与潜在恶性疾病过程的晚期并发症相反），我们预计在未来几个月将增加研究的进入，当然，等待FDA和IRB批准这样一个加速的时间表。